Dov Gertz
CEO & Co-Founder at Converge Bio, leveraging AI for drug discovery
Tel Aviv, Israel
Summary
Dov Gertz is a visionary entrepreneur and co-founder of Converge Bio, a company at the forefront of integrating Generative AI with biological data. He is dedicated to transforming drug discovery and development by training Large Language Models (LLMs) on DNA, RNA, and protein sequences to predict biological outcomes, contextualize insights, and generate novel molecular candidates. converge-bio+3
His academic background is rooted in bioinformatics, holding both a BSc and MSc from Tel Aviv University's Lautman excellence program. During his Master's research, he developed machine learning models that led to a discovery in the CRISPR field, culminating in a scientific publication co-authored with Nobel laureate Professor Jennifer Doudna, demonstrating his expertise in cutting-edge biotechnological research. theorg+5
Dov possesses a diverse professional history, including serving as an Entrepreneur In Residence at The Garage, a Search Language Specialist at Google, and an Intelligence Officer in Israeli Military Intelligence. This varied experience showcases his ability to navigate complex challenges, innovate in technological spaces, and lead within demanding environments. theorg+2